Puma Biotechnology (PBYI) Reaches New 1-Year High and Low at $50.15

Puma Biotechnology (NASDAQ:PBYI)’s share price reached a new 52-week high and low on Thursday . The stock traded as low as $50.15 and last traded at $51.15, with a volume of 13342 shares trading hands. The stock had previously closed at $51.45.

PBYI has been the subject of several research analyst reports. Zacks Investment Research upgraded Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Credit Suisse Group set a $106.00 price target on Puma Biotechnology and gave the company a “buy” rating in a report on Thursday, April 26th. Stifel Nicolaus set a $95.00 price target on Puma Biotechnology and gave the company a “buy” rating in a report on Friday, March 9th. Barclays cut their price target on Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, March 2nd. Finally, BidaskClub cut Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Friday, January 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $99.20.

The company has a current ratio of 1.91, a quick ratio of 1.87 and a debt-to-equity ratio of 0.85.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.26) by $0.61. The company had revenue of $66.50 million during the quarter, compared to analysts’ expectations of $67.33 million. During the same quarter last year, the firm posted ($1.16) EPS. sell-side analysts anticipate that Puma Biotechnology will post -3.83 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas boosted its holdings in shares of Puma Biotechnology by 314.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,129 shares of the biopharmaceutical company’s stock worth $1,001,000 after purchasing an additional 7,683 shares during the period. AXA purchased a new position in Puma Biotechnology during the 4th quarter valued at $1,052,000. C WorldWide Group Holding A S boosted its holdings in Puma Biotechnology by 9.3% during the 1st quarter. C WorldWide Group Holding A S now owns 23,882 shares of the biopharmaceutical company’s stock valued at $1,625,000 after acquiring an additional 2,026 shares during the period. Geode Capital Management LLC boosted its holdings in Puma Biotechnology by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 290,691 shares of the biopharmaceutical company’s stock valued at $28,733,000 after acquiring an additional 7,772 shares during the period. Finally, Castleark Management LLC boosted its holdings in Puma Biotechnology by 90.6% during the 4th quarter. Castleark Management LLC now owns 68,985 shares of the biopharmaceutical company’s stock valued at $6,819,000 after acquiring an additional 32,800 shares during the period. Hedge funds and other institutional investors own 97.95% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply